Literature DB >> 24046297

Reply to Mikulska et al.

Cynthia E Fisher1, Wendy Leisenring, Michael Boeckh, Tobias M Hohl.   

Abstract

Mesh：

Substances：

Year:  2013        PMID： 24046297      PMCID： PMC4007114          DOI： 10.1093/cid/cit568

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


× No keyword cloud information.
  4 in total

1.  Use of circulating galactomannan screening for early diagnosis of invasive aspergillosis in allogeneic stem cell transplant recipients.

Authors:  Johan Maertens; Johan Van Eldere; Jan Verhaegen; Erik Verbeken; Johny Verschakelen; Marc Boogaerts
Journal:  J Infect Dis       Date:  2002-10-08       Impact factor: 5.226

2.  Screening with serum galactomannan might be associated with better outcome than symptom-triggered galactomannan testing in allogeneic HSCT recipients with invasive aspergillosis.

Authors:  Malgorzata Mikulska; Anna Maria Raiola; Alessio Signori; Elisa Furfaro; Valerio Del Bono; Andrea Bacigalupo; Claudio Viscoli
Journal:  Clin Infect Dis       Date:  2013-09-17       Impact factor: 9.079

3.  Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: a prospective feasibility study.

Authors:  Johan Maertens; Koen Theunissen; Gregor Verhoef; Johnny Verschakelen; Katrien Lagrou; Eric Verbeken; Alexander Wilmer; Jan Verhaegen; Marc Boogaerts; Johan Van Eldere
Journal:  Clin Infect Dis       Date:  2005-09-29       Impact factor: 9.079

4.  The serum galactomannan index predicts mortality in hematopoietic stem cell transplant recipients with invasive aspergillosis.

Authors:  Cynthia E Fisher; A Michal Stevens; Wendy Leisenring; Steven A Pergam; Michael Boeckh; Tobias M Hohl
Journal:  Clin Infect Dis       Date:  2013-06-11       Impact factor: 9.079
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.